ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER Drug Patent Profile

Which patents cover Esmolol Hydrochloride In Plastic Container, and when can generic versions of Esmolol Hydrochloride In Plastic Container launch?

Esmolol Hydrochloride In Plastic Container is a drug marketed by Hq Spclt Pharma and is included in one NDA. There are two patents protecting this drug.

This drug has seven patent family members in seven countries.

The generic ingredient in ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER is esmolol hydrochloride. There are eight drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the esmolol hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Esmolol Hydrochloride In Plastic Container

A generic version of ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER was approved as esmolol hydrochloride by HIKMA on August 10^th, 2004.

Summary for ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER

International Patents:	7
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	112
DailyMed Link:	ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER at DailyMed

Recent Clinical Trials for ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Pakistan Institute of Medical Sciences	Phase 4
Muhammad Haroon Anwar	Phase 4
Consorcio Centro de Investigación Biomédica en Red (CIBER)	Phase 3

See all ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER clinical trials

Pharmacology for ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER

Drug Class	beta-Adrenergic Blocker
Mechanism of Action	Adrenergic beta-Antagonists

US Patents and Regulatory Information for ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER

ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hq Spclt Pharma	ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER	esmolol hydrochloride	SOLUTION;INTRAVENOUS	205703-001	Apr 7, 2016		RX	Yes	Yes	8,829,054		Y
Hq Spclt Pharma	ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER	esmolol hydrochloride	SOLUTION;INTRAVENOUS	205703-001	Apr 7, 2016		RX	Yes	Yes	8,835,505		Y

Expired US Patents for ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Hq Spclt Pharma	ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER	esmolol hydrochloride	SOLUTION;INTRAVENOUS	205703-001	Apr 7, 2016	6,310,094*PED
Hq Spclt Pharma	ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER	esmolol hydrochloride	SOLUTION;INTRAVENOUS	205703-001	Apr 7, 2016	6,528,540*PED

International Patents for ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER

See the table below for patents covering ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER around the world.

Country	Patent Number	Title	Estimated Expiration
Germany	60215129
Canada	2906031	COMPOSITION PHARMACEUTIQUE DE COSOLVANTS PRETE A L'UTILISATION DANS DES RECIPIENTS DE MATIERE PLASTIQUE FLEXIBLES MODIFIES (READY-TO-USE CO-SOLVENTS PHARMACEUTICAL COMPOSITION IN MODIFIED FLEXIBLE PLASTIC CONTAINER)
Czech Republic	304290	Vodná sterilní farmaceutická kompozice pro okamžité použití obsahující hydrochlorid esmololu a způsob její přípravy (Aqueous, sterile pharmaceutical composition for immediate use containing esmolol hydrochloride and process for preparing thereof)
Australia	2002309475
Czech Republic	20023825
Russian Federation	2286774	ПРЕПАРАТ ЭСМОЛОЛА (ESMOLOL-BASED PREPARATION)

ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER Market Analysis and Financial Projection Experimental

Esmolol Hydrochloride Market Dynamics and Financial Trajectory

Introduction to Esmolol Hydrochloride

Esmolol hydrochloride is a cardio-selective beta-blocker known for its rapid onset and short half-life, making it ideal for acute heart rate control, particularly in perioperative settings. First approved in 1986, it has become a crucial drug in managing various cardiovascular conditions[4].

Global Market Size and Growth

The global esmolol hydrochloride market is projected to exhibit steady growth over the coming years. According to various reports, the market size is expected to reach significant figures by 2030. For instance, IndustryARC estimates the market size to reach $487.2 million by 2030, growing at a CAGR of 3.5% from 2024 to 2030[5].

Compound Annual Growth Rate (CAGR)

The CAGR for the esmolol hydrochloride market varies slightly depending on the source, but it is consistently projected to be around 3.5% to 4.8%. MarkWide Research anticipates a CAGR of 4.8% from 2023 to 2030, while Cognitive Market Research estimates a CAGR of 4.0% from 2024 to 2031[1][2].

Regional Market Dynamics

North America

North America currently dominates the esmolol hydrochloride market, driven by the increasing incidence of cardiovascular diseases and the presence of well-established healthcare infrastructure. The region is expected to continue its significant growth, with a CAGR of 2.2% from 2024 to 2031[1][2].

Asia-Pacific

The Asia-Pacific region is anticipated to witness substantial growth, driven by rising healthcare expenditure, growing awareness of cardiovascular health, and an increase in lifestyle-related health issues. This region holds the majority market share and is expected to grow at a CAGR of 6.0% from 2024 to 2031[1][5].

Europe, Latin America, and Middle East & Africa

Europe is expected to grow at a CAGR of 2.5% from 2024 to 2031. Latin America and the Middle East & Africa are also expected to see growth, with CAGRs of 3.4% and 3.7%, respectively, during the same period[1].

Key Drivers of Market Growth

Increasing Prevalence of Cardiovascular Diseases

The rising prevalence of cardiovascular diseases is a major driver of the esmolol hydrochloride market. As the global population ages and lifestyles become more sedentary, the incidence of heart-related conditions increases, driving the demand for effective treatments like esmolol hydrochloride[2][5].

Growing Surgical Procedures

An increase in surgical procedures, particularly in regions like Asia-Pacific, is another significant driver. Esmolol hydrochloride's use in perioperative settings for heart rate control is crucial, making it a staple in many surgical protocols[1][5].

Advancements in Healthcare Infrastructure

Heightened investments in healthcare infrastructure, especially in emerging economies, are enhancing access to advanced treatment options. This includes the integration of telemedicine and digital health monitoring, which promotes early detection and intervention, further driving the demand for esmolol hydrochloride[5].

Regulatory Approvals and Expanding Indications

Regulatory approvals for expanded indications of esmolol hydrochloride have significantly contributed to market growth. Originally used for short-term heart rate control, it is now approved for broader applications such as perioperative hypertension and arrhythmia management in intensive care settings. These expanded indications are encouraging wider adoption in hospitals and clinics[5].

Competitive Landscape

The esmolol hydrochloride market is competitive, with key players including Pfizer Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Mylan N.V., and Aurobindo Pharma Ltd. These companies are investing in research and development to enhance the efficacy and safety of the drug, and they are also engaging in strategic partnerships, mergers, and acquisitions to strengthen their market presence[2].

Impact of Generic Alternatives

The availability of generic alternatives has intensified competition in the market, affecting pricing strategies and profitability for brand-name manufacturers. While this competition benefits healthcare systems and patients by making treatment options more accessible, it challenges brand-name producers to innovate and improve their marketing strategies to maintain market share[1].

Role in Clinics and Outpatient Procedures

Clinics are increasingly contributing to the growth of the esmolol hydrochloride market as they adopt the drug for outpatient procedures and cardiac management. The growing occurrence of cardiovascular conditions and the need for effective treatment alternatives in non-hospital settings enhance esmolol's usage, increasing its accessibility and availability in clinical practices[1].

Financial Trajectory

The financial trajectory of the esmolol hydrochloride market is positive, with steady growth projected over the next several years. Here are some key financial highlights:

• Global Market Size: Estimated to reach $487.2 million by 2030[5].
• CAGR: Ranging from 3.5% to 4.8% depending on the forecast period[1][2][5].
• Regional Growth: North America and Asia-Pacific are expected to be significant contributors to the market growth, with other regions also showing promising growth rates[1][2].

Key Takeaways

• Growing Demand: Driven by increasing cardiovascular diseases and surgical procedures.
• Regulatory Support: Expanded indications and regulatory approvals are boosting market growth.
• Competitive Landscape: Key players are innovating and forming strategic partnerships to maintain market share.
• Regional Dynamics: Asia-Pacific is expected to dominate the market, while North America continues to be a significant player.
• Financial Growth: Steady growth with a projected market size of $487.2 million by 2030.

FAQs

Q: What is the primary use of esmolol hydrochloride? A: Esmolol hydrochloride is primarily used for the management of various cardiovascular conditions, including supraventricular tachycardia, intraoperative and postoperative tachycardia, and hypertension[5].

Q: Which region dominates the esmolol hydrochloride market? A: The Asia-Pacific region currently holds the majority market share and is expected to continue its dominance due to rising healthcare expenditure and growing awareness of cardiovascular health[1][5].

Q: What is the impact of generic alternatives on the market? A: Generic alternatives have intensified competition, affecting pricing strategies and profitability for brand-name manufacturers, but they also make treatment options more accessible to patients[1].

Q: How does the growing geriatric population affect the market? A: The growing geriatric population increases the demand for cardiovascular interventions, as older adults are more susceptible to heart conditions that require precise cardiovascular control, driving the need for esmolol hydrochloride[5].

Q: What are the key drivers of market growth for esmolol hydrochloride? A: The key drivers include the increasing prevalence of cardiovascular diseases, growing surgical procedures, advancements in healthcare infrastructure, and regulatory approvals for expanded indications[1][2][5].

Cited Sources

1. Cognitive Market Research - Esmolol Hydrochloride Market Report 2024 (Global Edition)
2. MarkWide Research - Esmolol Hydrochloride Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2030
3. MarketResearchReports.com - Esmolol Hydrochloride API - Global Market Share and Ranking
4. PubChem - Esmolol Hydrochloride | C16H26ClNO4 | CID 104769
5. IndustryARC - Esmolol Hydrochloride Market – By Indication, By Sales Channel, By End Use, By Geography - Global Opportunity Analysis & Industry Forecast, 2024-2030